Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

about

Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.Primary malignant melanoma of the small intestine: a report of 2 cases and a review of the literature.Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.

P2860

Q48251370-AD01D38D-6394-4F41-BE2B-D36779B02A7A Q55003319-1ACB294C-DC08-48FC-8AF4-A74EA2BEB921 Q55311366-EE265344-0C84-4674-94C1-D9246052557E

P2860

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

Item

http://www.wikidata.org/entity/Q39329603

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@en

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@nl

type

Item

label

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@en

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@nl

prefLabel

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@en

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@nl

P1476

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

@en

P2093

David E Fisher

http://www.w3.org/2001/XMLSchema#string

Elizabeth H Byrne

http://www.w3.org/2001/XMLSchema#string

P2860

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

A comprehensive catalogue of somatic mutations from a human cancer genome

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

MITF: master regulator of melanocyte development and melanoma oncogene

P304

2143-2153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30444

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

S11

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28543699

http://www.w3.org/2001/XMLSchema#string

P932

5445935

http://www.w3.org/2001/XMLSchema#string

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

about

P2860

P2860

Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932